It reduces the endothelial expression of sirtuin 1 (SIRT1) in APOE-ε4, while increasing SIRT1 levels in APOE-ε3 carriers, which potentially weakens inherent barrier dysfunction and glucose hypometabolism associated with AD risk (Weber et al., 2025). This evidence concerns the gene SIRT1 and Alzheimer disease.